By Dr Alberto Ospina Stella

Preprints

Aggarwal A; Ognenovska S; Ison T; Fichter C; Milogiannakis V; Afzal M; Stella AO; Waters S; Esneau C; Bartlett N; Pöhlmann S; Hoffmann M; Burrell L; Patel S; Ellis S; Wehrhahn M; Martinez E; Ginn A; Churchill M; Angelovich T; Rawlinson W; Yeang M; Kok J; Sintchenkov V; Parry R; Sng J; Neely G; Moreno C; Loo L; Kelleher A; Brilot F; Khromykh A; Turville S, 2025, Replication of SARS-CoV-2 Omicron lineages is defined by TMPRSS2 use in environments where ACE2 is complexed with solute carriers SLC6A19 and SLC6A20, http://dx.doi.org/10.1101/2025.07.07.663433

Moreno C; Castanheira F; Stella AO; Chung F; Aggarwal A; Cole A; Loo L; Dupuy A; Kong Y; Hagimola L; Fenwick J; Coleman P; Willson M; Bui-Marinos M; Hesselson D; Gamble J; Passam F; Turville S; Kubes P; Neely G, 2023, P-Selectin promotes SARS-CoV-2 interactions with platelets and the endothelium, http://dx.doi.org/10.1101/2023.02.13.528235

Loo L; Waller M; Cole A; Stella A; Moreno C; Denes C; Hamoudi Z; Chung F; Aggarwal A; Low J; Patel K; Siddiquee R; Mackay J; Turville S; Hesselson D; Neely G, 2022, LRRC15 suppresses SARS-CoV-2 infection and controls collagen production, http://dx.doi.org/10.21203/rs.3.rs-1172665/v1

Phetsouphanh C; Khoo WH; Jackson K; Klemm V; Howe A; Aggarwal A; Akerman A; Milogiannakis V; Stella AO; Rouet R; Schofield P; Faulks M; Law H; Danwilai T; Starr M; Munier ML; Christ D; Singh M; Croucher P; Brilot-Turville F; Turville S; Phan TG; Dore G; Darley D; Cunningham P; Matthews G; Kelleher A; Zaunders J, 2022, High titre neutralizing antibodies in response to SARS-CoV-2 infection require RBD-specific CD4 T cells that include proliferative memory cells, http://dx.doi.org/10.1101/2022.07.22.22277947

Aggarwal A; Stella A; Akerman A; Walker G; Milogiannakis V; McAllery S; Esneau C; Silva MR; Lu Y; Forster C; Hal SV; Mathivanan V; Fitcher C; Hoppe AC; Munier ML; Darley D; Matthews G; Starck D; Robosa R; Bartlett N; Rawlinson W; Kelleher A; Turville S, 2022, Rapid isolation and resolution immune evasion and viral fitness across contemporary SARS-CoV-2 variants, http://dx.doi.org/10.21203/rs.3.rs-1210846/v1

Aggarwal A; Stella A; Walker G; Akerman A; Milogiannakis V; Brilot F; Amatayakul-Chantler S; Roth N; Coppola G; Schofield P; Jackson J; Lenthall H; Mazigi O; Langley D; Lu Y; Forster C; McAllery S; Mathivanan V; Fitcher C; Hoppe AC; Munier CML; Jack H-M; Cromer D; Darley D; Matthews G; Christ D; Khoury D; Davenport M; Rawlinson W; Kelleher A; Turville S, 2022, SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern, http://dx.doi.org/10.21203/rs.3.rs-1207364/v1

Li L; Honda-Okubo Y; Huang Y; Jang H; Carlock MA; Baldwin J; Piplani S; Bebin-Blackwell AG; Forgacs D; Sakamoto K; Stella A; Turville S; Chataway T; Colella A; Triccas J; Ross TM; Petrovsky N, 2021, Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection, http://dx.doi.org/10.1101/2021.07.03.451026

Garcia-Valtanen P; Hope C; Masavuli M; Lip Yeow AE; Balachandran H; Mekonnen Z; Al-Delfi Z; Abayasingam A; Agapiou D; Stella AO; Aggarwal A; Gummow J; Ferguson C; O’Connor S; McCartney E; Lynn D; Maddern G; Gowans E; Reddi BAJ; Shaw D; Kok-Lim C; Turville S; Beard M; Weiskopf D; Sette A; Bull R; Barry S; Grubor-Bauk B, 2021, COVID-19 convalescents exhibit deficient humoral and T cell responses to variant of concern Spike antigens at 12 month post-infection, http://dx.doi.org/10.1101/2021.11.08.21266035

Loo L; Waller M; Moreno C; Cole A; Stella AO; Pop O-T; Jochum A-K; Ali OH; Denes C; Denes C; Hamoudi Z; Chung F; Aggarwal A; Low J; Patel K; Siddiquee R; Kang T; Mathivanan S; Mackay J; Flatz L; Hesselson D; Turville S; Neely G, 2021, Fibroblast-expressed LRRC15 suppresses SARS-CoV-2 infection and controls antiviral and antifibrotic transcriptional programs, http://dx.doi.org/10.1101/2021.11.09.467981

Counoupas C; Pino P; Stella A; Ashley C; Lukeman H; Bhattacharyya N; Tada T; Anchisi S; Metayer C; Martinis J; Aggarwal A; Dcosta B; Kint J; Wurm M; Landau N; Steain M; Turville S; Wurm F; David S; Triccas J, 2021, Neutralising antibodies against the SARS-CoV-2 Delta variant induced by Alhydroxyquim-II-adjuvanted trimeric spike antigens, http://dx.doi.org/10.1101/2021.08.18.456891

Tea F; Stella AO; Aggarwal A; Darley DR; Pilli D; Vitale D; Merheb V; Lee FXZ; Cunningham P; Walker GJ; Brown DA; Rawlinson WD; Isaacs SR; Mathivanan V; Hoffman M; Pöhlmann S; Dwyer DE; Rockett R; Sintchenko V; Hoad VC; Irving DO; Dore GJ; Gosbell IB; Kelleher AD; Matthews GV; Brilot F; Turville SG, 2020, SARS-CoV-2 neutralizing antibodies; longevity, breadth, and evasion by emerging viral variants, http://dx.doi.org/10.1101/2020.12.19.20248567

Counoupas C; Johansen M; Stella A; Nguyen D; Ferguson A; Aggarwal A; Bhattacharyya N; Grey A; Patel K; Siddiquee R; Stewart E; Feng C; Hansbro N; Palendira U; Steain M; Saunders B; Low J; Mackay J; Kelleher A; Britton W; Turville S; Hansbro P; Triccas J, 2020, A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilizing immunity against SARS-CoV-2 infection in mice, http://dx.doi.org/10.1101/2020.12.10.419044

Walker G; Naing Z; Stella AO; Yeang M; Caguicla J; Ramachandran V; Isaacs S; Agapiou D; Bull R; Stelzer-Braid S; Daly J; Gosbell I; Hoad V; Irving D; Pink J; Turville S; Kelleher A; Rawlinson W, 2020, SARS Coronavirus-2 microneutralisation and commercial serological assays correlated closely for some but not all enzyme immunoassays, http://dx.doi.org/10.1101/2020.12.07.20245696

Walker G; Clifford V; Bansal N; Stella AO; Turville S; Stelzer-Braid S; Klein L; Rawlinson W, 2020, SARS-CoV-2 in human milk is inactivated by Holder pasteurization but not cold storage, http://dx.doi.org/10.1101/2020.06.18.20134395

Aggarwal A; Ospina Stella A; Henry C; Narayan K; Turville S, 2019, HIV corruption of the Arp2/3-Cdc42-IQGAP1 axis to hijack cortical F-Actin to promote cell-cell viral spread, http://dx.doi.org/10.1101/2019.12.13.873612

Balachandran H; Phetsouphanh C; Agapiou D; Adhikari A; Rodrigo C; Hammoud M; Shrestha LB; Keoshkerian E; Gupta M; Turville S; Christ D; King C; Sasson S; Bartlett A; Grubor-Bauk B; Rawlinson W; Aggarwal A; Stella AO; Klemm V; Mina MM; Post JJ; Hudson B; Gilroy N; Konecny P; Ahlenstiel G; Dwyer D; Sorrell TC; Kelleher A; Tedla N; Lloyd AR; Martinello M; Bull RA, Maintenance of Broad Neutralising Antibodies and Memory B Cells 12 Months Post-Infection Is Predicted by SARS-CoV-2 Specific CD4+ T Cell Responses, http://dx.doi.org/10.2139/ssrn.3920641

Back to profile page